Developer docs
API playgroundTry for free, no card

Search company profiles

Temmler Werke Holding GmbH

Full company profile

uuid005ftw9

Namestring
Temmler Werke Holding GmbH
Legal namestring
Aenova Holding GmbH
Websiteurl
temmler.eu
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Temmler Werke Holding GmbH operates under the trade name Aenova Group and is a German-domiciled, privately held Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical and healthcare industry, headquartered in Starnberg-Percha, Germany. The company describes itself as a "worldwide leading" contract manufacturer and operates three interconnected service lines: Pharmaceutical Manufacturing (contract production of tablets, capsules, and other dosage forms), Development & Technology (formulation, analytical development, and technology transfer), and Animal Health (specialized veterinary pharmaceutical manufacturing). Additional capabilities include a Sterile Technologies Competence Center in Latina and an in-house global Pharmacovigilance function covering adverse reaction monitoring and regulatory reporting for medicinal products, medical devices, and cosmetics.

The business model is enterprise B2B contract manufacturing, with revenue generated through long-term, individually negotiated manufacturing contracts with pharmaceutical and healthcare customers reached via direct enterprise field sales. Pricing is not publicly disclosed. The company maintains a corporate website, social channels (LinkedIn, Instagram, Facebook), and a bi-monthly CDMO newsletter as top-of-funnel marketing infrastructure, and is governed by Managing Directors Jan Kengelbach and Dr. Peter Waller. In June 2026, the firm achieved an EcoVadis Silver Medal for ESG performance, and appointed a new Managing Director for its Latina sterile site, with the Aenova Annual Report 2025 having been published in 2025.

The source data does not disclose revenue, employee headcount at the operating level (the firmographic figure of 19 appears to reflect the holding entity rather than the group), ownership structure beyond management, or a historical M&A record, so scale claims rest on self-reported positioning rather than disclosed financial metrics.

Short descriptiontext

Temmler Werke Holding GmbH, operating as Aenova Group, is a German privately held pharmaceutical CDMO offering contract manufacturing, development, animal health, and sterile technologies services to pharmaceutical and healthcare companies worldwide through long-term enterprise contracts.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersStarnberg (Percha), Germany
HQ citystring
Starnberg (Percha)
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical contract manufacturing, contract development services, sterile dosage manufacturing, animal health manufacturing, pharmaceutical formulation development
Industry4 codes
1Drug Substance–Drug Product Integrated CDMO
CodeHLAGABAGPrimaryYes
2Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
CodeHLAGABABPrimaryNo
3Clinical Trial Material (CTM) Manufacturing & Supply CDMO
CodeHLAGABAKPrimaryNo
4Contract Development & Manufacturing for Generics (CDMO/CMO)
CodeHLAIABAIPrimaryNo
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Contract Manufacturing
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Manufacturing Services
TypeProfessional Services
Description

CDMO services providing pharmaceutical development and manufacturing to pharmaceutical and healthcare companies. Revenue generated through long-term manufacturing contracts with pharmaceutical customers.

aenova-group.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Temmler Werke Holding GmbH operates the Aenova Group, a global contract development and manufacturing organization (CDMO) for the pharmaceutical and healthcare industry. Its core offering covers pharmaceutical contract manufacturing of tablets, capsules, and sterile dosage forms, alongside pharmaceutical development and technology services (formulation, analytical development, technology transfer) and specialized animal health product manufacturing.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Aenova Group is a worldwide leading Contract Development and Manufacturing Organization (CDMO) serving the pharmaceutical and healthcare industry. The company operates as a single unified platform offering three interconnected service lines: Pharmaceutical Manufacturing (core manufacturing of dosage forms), Development & Technology (formulation and analytical development services), and Animal Health (specialized veterinary products). Additional services include Pharmacovigilance monitoring and specialized Sterile Technologies capabilities at its Latina facility. The company provides end-to-end services from development through commercial manufacturing for its pharmaceutical clients.

Product and service4 records
1Pharmaceutical Manufacturing
CategoryContract Manufacturing
Description

Comprehensive contract manufacturing services for pharmaceutical products including tablets, capsules, and other dosage forms for global pharmaceutical and healthcare companies.

2Development & Technology
CategoryContract Development
Description

Pharmaceutical development services including product formulation, analytical development, and technology transfer for pharmaceutical contract manufacturing clients.

3Animal Health
CategoryContract Manufacturing
Description

Specialized pharmaceutical products and contract manufacturing services for animal health and veterinary pharmaceutical applications.

4Pharmacovigilance Services
CategoryRegulatory Services
Description

Worldwide safety monitoring of pharmaceutical products including adverse reaction tracking, side effect monitoring, and regulatory reporting for medicinal products, medical devices, and cosmetics.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Lonza is one of the world's largest CDMOs spanning small molecules, biologics, and cell & gene therapy manufacturing. It competes with Aenova for pharmaceutical contract manufacturing customers and is a broad incumbent in the same end-to-end CDMO category.

TypeDirect peer
Description

Fareva is a privately held French-headquartered pharmaceutical contract manufacturer offering sterile, solid, and semi-solid dose manufacturing across multiple European sites — directly comparable to Aenova's integrated European CDMO footprint and service portfolio.

TypeDirect peer
Description

Recipharm is a European-headquartered CDMO offering contract development and manufacturing of pharmaceutical formulations including solid, semi-solid, and sterile dosage forms — directly comparable to Aenova across pharma contract manufacturing.

TypeDirect peer
Description

CordenPharma is a CDMO providing API manufacturing and drug product services including solid dose and sterile injectable fill-finish — directly comparable to Aenova's integrated Drug Substance–Drug Product CDMO offering for pharma customers.

TypeDirect peer
Description

Vetter is a specialist CDMO focused on aseptic filling of injectable pharmaceuticals and lyophilization, directly comparable to Aenova's Sterile Technologies Competence Center in Latina and its sterile fill-finish service line.

TypeDirect peer
Description

Catalent is a leading global CDMO offering solid oral dose, sterile fill-finish, and development services to pharma companies — a directly comparable integrated pharmaceutical contract manufacturer to Aenova across the same dosage form categories.

TypeDirect peer
Description

Siegfried is a Swiss-headquartered CDMO specializing in solid oral dosage forms, sterile manufacturing, and APIs — directly comparable to Aenova's pharmaceutical manufacturing and Development & Technology service lines for European and global pharma customers.

TypeDirect peer
Description

PCI Pharma Services is a global CDMO providing integrated pharmaceutical development, manufacturing, and packaging services including sterile fill-finish — directly comparable to Aenova's contract manufacturing and packaging capabilities.

TypeBroad incumbent
Description

BioXcellence is the CDMO arm of Boehringer Ingelheim offering contract biopharmaceutical and fill-finish manufacturing services. As a large incumbent with overlapping pharmaceutical contract manufacturing capabilities, it competes with Aenova for pharma outsourcing contracts.

TypeDirect peer
Description

Almac is a global CDMO offering pharmaceutical development, analytical services, and commercial manufacturing of solid oral dose and sterile products — a directly comparable integrated CDMO serving pharma companies across similar dosage form categories as Aenova.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Temmler Werke Holding GmbH

Pharmaceutical Contract Manufacturingtemmler.eu

Temmler Werke Holding GmbH, operating as Aenova Group, is a German privately held pharmaceutical CDMO offering contract manufacturing, development, animal health, and sterile technologies services to pharmaceutical and healthcare companies worldwide through long-term enterprise contracts.

What Temmler Werke Holding GmbH does

Temmler Werke Holding GmbH operates under the trade name Aenova Group and is a German-domiciled, privately held Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical and healthcare industry, headquartered in Starnberg-Percha, Germany. The company describes itself as a "worldwide leading" contract manufacturer and operates three interconnected service lines: Pharmaceutical Manufacturing (contract production of tablets, capsules, and other dosage forms), Development & Technology (formulation, analytical development, and technology transfer), and Animal Health (specialized veterinary pharmaceutical manufacturing). Additional capabilities include a Sterile Technologies Competence Center in Latina and an in-house global Pharmacovigilance function covering adverse reaction monitoring and regulatory reporting for medicinal products, medical devices, and cosmetics.

The business model is enterprise B2B contract manufacturing, with revenue generated through long-term, individually negotiated manufacturing contracts with pharmaceutical and healthcare customers reached via direct enterprise field sales. Pricing is not publicly disclosed. The company maintains a corporate website, social channels (LinkedIn, Instagram, Facebook), and a bi-monthly CDMO newsletter as top-of-funnel marketing infrastructure, and is governed by Managing Directors Jan Kengelbach and Dr. Peter Waller. In June 2026, the firm achieved an EcoVadis Silver Medal for ESG performance, and appointed a new Managing Director for its Latina sterile site, with the Aenova Annual Report 2025 having been published in 2025.

The source data does not disclose revenue, employee headcount at the operating level (the firmographic figure of 19 appears to reflect the holding entity rather than the group), ownership structure beyond management, or a historical M&A record, so scale claims rest on self-reported positioning rather than disclosed financial metrics.

Temmler Werke Holding GmbH firmographics

Firmographics
Name
Temmler Werke Holding GmbH
Legal name
Aenova Holding GmbH
Website
https://temmler.eu
Company type
Private
Operating status
Operating
Headcount range
11–50 employees
Short description
Temmler Werke Holding GmbH, operating as Aenova Group, is a German privately held pharmaceutical CDMO offering contract manufacturing, development, animal health, and sterile technologies services to pharmaceutical and healthcare companies worldwide through long-term enterprise contracts.
Ownership category
akta.pro rank

Temmler Werke Holding GmbH industry classification

Industry
Product category
Pharmaceutical Contract Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro primary industry
Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
akta.pro secondary industries
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

  • Pharmaceutical contract manufacturing
  • Contract development services
  • Sterile dosage manufacturing
  • Animal health manufacturing
  • Pharmaceutical formulation development

Where Temmler Werke Holding GmbH is headquartered

Location

Headquarters

HQ city
Starnberg (Percha)
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Temmler Werke Holding GmbH business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Manufacturing Services: CDMO services providing pharmaceutical development and manufacturing to pharmaceutical and healthcare companies. Revenue generated through long-term manufacturing contracts with pharmaceutical customers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Temmler Werke Holding GmbH product offering

Product offering

Core offering

Temmler Werke Holding GmbH operates the Aenova Group, a global contract development and manufacturing organization (CDMO) for the pharmaceutical and healthcare industry. Its core offering covers pharmaceutical contract manufacturing of tablets, capsules, and sterile dosage forms, alongside pharmaceutical development and technology services (formulation, analytical development, technology transfer) and specialized animal health product manufacturing.

Product overview

Aenova Group is a worldwide leading Contract Development and Manufacturing Organization (CDMO) serving the pharmaceutical and healthcare industry. The company operates as a single unified platform offering three interconnected service lines: Pharmaceutical Manufacturing (core manufacturing of dosage forms), Development & Technology (formulation and analytical development services), and Animal Health (specialized veterinary products). Additional services include Pharmacovigilance monitoring and specialized Sterile Technologies capabilities at its Latina facility. The company provides end-to-end services from development through commercial manufacturing for its pharmaceutical clients.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pharmaceutical Manufacturing Comprehensive contract manufacturing services for pharmaceutical products including tablets, capsules, and other dosage forms for global pharmaceutical and healthcare companies.
  • Development & Technology Pharmaceutical development services including product formulation, analytical development, and technology transfer for pharmaceutical contract manufacturing clients.
  • Animal Health Specialized pharmaceutical products and contract manufacturing services for animal health and veterinary pharmaceutical applications.
  • Pharmacovigilance Services Worldwide safety monitoring of pharmaceutical products including adverse reaction tracking, side effect monitoring, and regulatory reporting for medicinal products, medical devices, and cosmetics.

Companies that use Temmler Werke Holding GmbH

Customer profile

Segments2 records

Ideal customer profiles2 records

Temmler Werke Holding GmbH technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Temmler Werke Holding GmbH partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Temmler Werke Holding GmbH competitors and assessment

Company assessment

Broad incumbents

  • Lonza Group: Lonza is one of the world's largest CDMOs spanning small molecules, biologics, and cell & gene therapy manufacturing. It competes with Aenova for pharmaceutical contract manufacturing customers and is a broad incumbent in the same end-to-end CDMO category.
  • Boehringer Ingelheim BioXcellence: BioXcellence is the CDMO arm of Boehringer Ingelheim offering contract biopharmaceutical and fill-finish manufacturing services. As a large incumbent with overlapping pharmaceutical contract manufacturing capabilities, it competes with Aenova for pharma outsourcing contracts.

Direct peers

  • Fareva: Fareva is a privately held French-headquartered pharmaceutical contract manufacturer offering sterile, solid, and semi-solid dose manufacturing across multiple European sites — directly comparable to Aenova's integrated European CDMO footprint and service portfolio.
  • Recipharm: Recipharm is a European-headquartered CDMO offering contract development and manufacturing of pharmaceutical formulations including solid, semi-solid, and sterile dosage forms — directly comparable to Aenova across pharma contract manufacturing.
  • CordenPharma: CordenPharma is a CDMO providing API manufacturing and drug product services including solid dose and sterile injectable fill-finish — directly comparable to Aenova's integrated Drug Substance–Drug Product CDMO offering for pharma customers.
  • Vetter Pharma: Vetter is a specialist CDMO focused on aseptic filling of injectable pharmaceuticals and lyophilization, directly comparable to Aenova's Sterile Technologies Competence Center in Latina and its sterile fill-finish service line.
  • Catalent: Catalent is a leading global CDMO offering solid oral dose, sterile fill-finish, and development services to pharma companies — a directly comparable integrated pharmaceutical contract manufacturer to Aenova across the same dosage form categories.
  • Siegfried Holding: Siegfried is a Swiss-headquartered CDMO specializing in solid oral dosage forms, sterile manufacturing, and APIs — directly comparable to Aenova's pharmaceutical manufacturing and Development & Technology service lines for European and global pharma customers.
  • PCI Pharma Services: PCI Pharma Services is a global CDMO providing integrated pharmaceutical development, manufacturing, and packaging services including sterile fill-finish — directly comparable to Aenova's contract manufacturing and packaging capabilities.
  • Almac Group: Almac is a global CDMO offering pharmaceutical development, analytical services, and commercial manufacturing of solid oral dose and sterile products — a directly comparable integrated CDMO serving pharma companies across similar dosage form categories as Aenova.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Temmler Werke Holding GmbH social profiles

Digital presence

Temmler Werke Holding GmbH compliance and trust

Trust signal

Compliance1 record

Temmler Werke Holding GmbH financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Temmler Werke Holding GmbH leadership team

Management profile

Number of profiles

Profiles2 records

Temmler Werke Holding GmbH funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Temmler Werke Holding GmbH M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Temmler Werke Holding GmbH

What does Temmler Werke Holding GmbH do?

Temmler Werke Holding GmbH operates the Aenova Group, a global contract development and manufacturing organization (CDMO) for the pharmaceutical and healthcare industry. Its core offering covers pharmaceutical contract manufacturing of tablets, capsules, and sterile dosage forms, alongside pharmaceutical development and technology services (formulation, analytical development, technology transfer) and specialized animal health product manufacturing.

Is Temmler Werke Holding GmbH a public or private company?

Temmler Werke Holding GmbH is a private company. It is classified as unknown and is currently operating.

When was Temmler Werke Holding GmbH founded?

Temmler Werke Holding GmbH was founded in -1. It employs 11 to 50 people.

Where is Temmler Werke Holding GmbH based?

Temmler Werke Holding GmbH is headquartered in Starnberg (Percha), Germany, in the Europe region.

How does Temmler Werke Holding GmbH make money?

One revenue line is on record: contract Manufacturing Services.

Who are Temmler Werke Holding GmbH's main competitors?

Broad incumbents on record are Lonza Group and Boehringer Ingelheim BioXcellence. Direct peers are Fareva, Recipharm, CordenPharma, Vetter Pharma, Catalent, Siegfried Holding, PCI Pharma Services and Almac Group.

Does Temmler Werke Holding GmbH have an API?

No public API is recorded for Temmler Werke Holding GmbH.

What industry is Temmler Werke Holding GmbH in?

Temmler Werke Holding GmbH's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales